TREM2 Bicycle

**TREM2 Bicycle** is an early preclinical **bicyclic peptide** therapeutic concept from **Bicycle Therapeutics** designed to activate **triggering receptor expressed on myeloid cells 2** on microglia, with the apparent goal of enhancing microglial phagocytic and homeostatic activity in neurodegenerative disease, especially **Alzheimer's disease**. Publicly available information indicates that Bicycle Therapeutics has presented this program as a **TREM2 agonist Bicycle** and, in at least one company presentation, as a **TfR1 Bicycle-TREM2 agonist Bicycle**, implying a bifunctional or conjugated CNS-delivery strategy in which a **transferrin receptor 1** binding Bicycle may be used to facilitate blood-brain barrier transcytosis while a TREM2-binding Bicycle engages microglia in the brain. No clear, molecule-specific clinical code, formulation, or human development record was identified in public sources, so this appears to be a **discovery-stage research program** rather than a named clinical candidate.

Other names

TREM2 BicycleTREM-2 BicycleTREM 2 BicycleTfR1 Bicycle-TREM2 agonist BicycleTfR-1 Bicycle-TREM2 agonist BicycleTfR 1 Bicycle-TREM2 agonist Bicycle